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Summary: Thrombocytic, haemostatic and fibrinolytic quantities were investigated in 47 patients with cerebral
infarction and 34 patients with cerebral haemorrhage. Sixteen of the infarction patients and ten patients of
the haemorrhage group were on acetylsalicylic acid medication. Of the remaining 55 patients without
acetylsalicylic medication 21/31 = 67.7% of the patients in the infarction group and 9/24 = 37.5% of the
patients in the bleeding group had unphysiologically enhanced ADP-induced platelet aggregation. With regard
to the coagulation and fibrinolysis markers no significant differences were found between the two groups. In
both groups, coagulation activity markers (fibrin monomer and thrombin-antithrombin III), as well as D-
dimers were significantly higher than in controls in a high proportion of cases. In 5/47 of the infarction
patients and in 3/34 of the haemorrhage patients the fibrin monomer levels were elevated to such an extent,
that it can be considered as low grade disseminated intravascular coagulation.
In the cerebral haemorrhage group, 80.3% of the patients who subsequently died showed a significantly
enhanced fibrin monomer concentration, compared with 28.6% of those who survived. The corresponding
frequencies for D-dimer were 100% compared with 66.7%.
In the cerebral infarction group, the only analytical quantity showing a significant difference between patients
with a fatal outcome and those with a non-fatal outcome was ADP (2 μηιοΐ/l) induced platelet aggregation
(83.3% in the fatal group, 40.0% in the non-fatal group).
In recent years a number of new, more sensitive quan-
n o uction tities have become available for testing for clotting
Cerebral infarction and cerebral haemorrhage are and fibrinolysis: fibrin monomers (4), thombin-an-
events which may be accompanied by coagulation tithrombin-III complexes (5) and D-dimers (6). These
activation and (reactive) fibrinolysis. The clinical sig- quantities may be useful for sensitive monitoring of
nificance and relevance of coagulation and platelet the course of the disease, for the better follow-up of
abnormalities (1, 2) on the one hand and of coagu- the therapy and the possible estimation of the prog-
lation and fibrinolysis factors (3) on the other hand nosis.
have been studied earlier. None of the factors studied Aim of this study was to get more insight in the extent
so far has shown a significant difference from normal of platelet coagulation and fibrinolysis activation after
in cases of cerebral infarction and cerebral bleeding. recent cerebral bleeding and infarction.
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Tab. 1. Basic data of the patients.
Cerebral infarction
(n = 47)
Cerebral haemorrhage
(n = 34)
Mean age 65.6 ± 13.6 (SD) years 71/0 ±11.6 (SD) years
Number
Males
Females
Diabetes mellitus
History of hypertension
Patients on acetylsalicylic acid
21
26
13
15
16
44.6
55.4
27.7
31.9
34.0
20
14
0
14
10
58.8
41.2
0
41.1
29.4
Patients
Venous blood samples were collected from 81 patients, 47 with
cerebral infarction (21 males, 26 females, mean age ± 2 SD:
65.5 ± 13.6; range 39-87 years) and 34 with cerebral bleeding
(20 males, 14 females, mean age ± 2SD: 71.0 ±11.6; range
42-90 years). The basic data of the patients are summarized
in table 1. Blood samples were taken immediately after admis-
sion to the Department of Neurology and before any therapeu-
tic measures. The documentable day of the ictus was one to
eleven days previously (mean 3.3 days).
All patients had computer tomography (CT-scanning) to con-
firm the diagnosis. In the group of patients with cerebral hae-
morrhage the extent of the bleeding was estimated from the
computer tomography pictures. The sizes displayed a wide
range from 1.5 to 104 ml (median 11 ml). There was no cor-
relation between the extent of bleeding and the extent of co-
agulation activation.
The size of the brain lesion in the infarction group is difficult
to assess with computer tomography. The most likely stroke
mechanism in the infarction patient group was atherothrom-
botic in 30 of the 47, cardioembolic in 10 and lacunar in 7
patients. No patient exhibited a primary haemostatic defect nor
was any patient known to have a familial history of thrombosis.
Laboratory reference values were obtained from 50 subjectively
healthy volunteers, age range 24 to 50 years. The mean values
± 2 SD were taken as the reference ranges. The control group
was age and sex matched (n = 135, age range 24—90 years,
mean 55.3 years) and consisted of subjectively healthy patients
visiting the hospital pre-operatively before minor elective sur-
gical treatment. The usual pre-operative laboratory investiga-
tions were normal. The participants were free of acute and
chronic disease. Subjects with heart disease, known cancer or
previous histories of thrombotic events or haematoma were
excluded. Controls were not taking medication known to in-
terfere with coagulation.
Samples
The blood samples were drawn between 8.30 and 9.00 a.m.
Citrated plasma was prepared by centrifugation of nine volumes
of freshly drawn blood with one volume of trisodium citrate
(0.11 mol/1) for 10 min at 25 °C (1600g). The plasmas were
stored at — 70 °C in plastic tubes and thawed with tap water
for 5 min before use.
The platelet aggregation tests were performed on platelet-rich
plasma which was prepared by immediate centrifugation of
citrated blood (prepared as described above) at 200 g for 10
minutes at room temperature. After gentle aspiration of the
platelet-rich plasma, using a plastic pipette, the remaining blood
was centrifuged at 2000 g for 10 min at room temperature; the
resulting platelet-poor plasma was aspirated and subsequently
centrifuged at 10 000 g at 4°C for 10 min to obtain platelet-
free plasma. Platelet-rich plasma and platelet-free plasma were
used for standardization of the end concentration of the platelet
count in the test.
The ADP-induced aggregations were performed at a platelet
concentration of 200 χ 109/1.
Methods
The chromogenic Coa-set fibrin monomer test of Kabi Vitrum
Diagnostica was used for the fibrin monomer determinations.
For the thrombin-antithrombin III determinations we used an
Elisa test kit from Behring (Behring Corp, Marburg, Germany).
The fibrin degradation products were determined with the D-
dimer test (Boehringer Mannheim, Mannheim, Germany). The
D-dimer test is a specific Elisa test for the determination of
degradation products of cross-linked fibrin only and not of
fibrinogen. The ADP-induced platelet aggregations were meas-
ured by a turbidimetric method using a Daiichi dual channel
aggregation device (Daiichi Kyoto, Japan). The link between
test concentrations and results is given in table 2.
Statist ical analysis
For the comparison of the patient groups with each other and
of each patient group with the reference group, the Mann-
Whitney-\J test was employed. The %2-test was employed to test
the percentage difference between the various methods.
Results
Table 2 summarizes the results and criteria for nor-
mality of the different aggregation tests carried out
in this study. We found enhanced 2 · 10~6 mol/1 ADP-
induced platelet aggregations in 21/31 of the infarc-
tion patients and in 9/24 of the bleeding patients.
The clotting and fibrinolysis quantities did not differ
significantly between the groups with cerebral hae-
morrhage and with cerebral infarction (results not
shown).
Comparison of the analytical quantities of both pa-
tient groups with the upper limit of the reference
ranges (tab. 3) showed a high frequency of elevated
concentrations for fibrin monomer (61.7 and 44.1),
for thrombin-antithrombin III (57.4% and 41.2%)
and for D-dimer (76.6% and 79.4) for cerebral iri-
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farction and haemorrhage respectively. Comparison In table 4 the patient groups are subdivided according
of the median values of these quantities of both pa^ to the clinical outcome (fatal, non-fatal) and the ex-
tient groups with the control group showed that the tent of the coagulation, fibrinolysis and platelet acti-
differences for all three quantities were highly signif- vation (i. e. concentrations above the upper limit of
icant. the respective reference ranges). The different fre-
Tab. 2. The criteria for normality and the results of the different types of aggregation tests.
Aggregation inducer
ADP (μιηοΐ/ΐ)
0.2
ADP (μιηοΐ/ΐ)
2
ADP (μιηο]/1)
10
Tab. 3. Coagulation and
Whimey-U test).
Analytes
(reference ranges)
Fibrin monomer
(8.4- 13.2 nmol/I)
Thrombin-antithrombin
III complex
(1.0-4.1 μg/l)
D-dimer
(0-450 μδ/1)
Criteria for normality
Aggregation
pattern
aggregation absent
reversible
non reversible
Aggregation
maximum
(change in light
transmission)
0
<50
>50
fibrinolysis markers of the patient groups in comparison
IQR = interquartile range.
Cerebral Cerebral
infarction haemorrhage
(n = 47) (ή = 34)
Median Median
(IQR) (IQR)
14.3 12.2
(8.5) (5.0)
5.4 3.2
(6-7) (6.9)
960 1137
(864) (2792)
Control Significance
group p-value
(n = 135)
Median Cerebral
(IQR) infarction
10.5 <0.001*
(2.0)
2.3 < 0.001*
(1.4)
199 < 0.0001*
(146)
Abnormal number
Cerebral
infarction
2/31 = 6.5%
21/31 = 67.7%
0/31 = 0%
Cerebral
haemorrhage
2/24 = 8.3%
9/24 = 37.5%
1/24 = 4.2%
with the control group (n = 135). (* Mann-
Cerebral
haemorrhage
<0.01*
<0.01*
< 0.0001*
Patients exceeding the upper
reference limit of laboratory
reference range
Cerebral Cerebral
infarction haemorrhage
29/47 15/34
27/47 14/34
36/47 27/34
Tab. 4. Percentages of values of the various analytes above the upper limit of the respective reference ranges (for fibrin monomer
13.2 nmol/1; for thrombin-antithrombin III 4.1 μg/l arid for D-dimer 450 μg/l).
%2-test on the numbers showed significance for IJp < 0.02; 2)p < 0.05 and 3)p < 0.05
Analytes
(reference ranges)
ADP (2 · 10~6 mol/1) platelet
aggregation
Percentages of values of the various analytes above the upper limit
of the reference range
Fibrin monomers
(8.4 -13.2 nmol/I)
Thrombin-antithrombin
III complex
(1.0-4.1 μβ/1) ,
D-dimer
(0-450 μβ/1)
Cerebral infarction
fatal outcome non-fatal outcome
83.3 60.0
66.7 57.5
83.3 77.5
Cerebral haemorrhage
fatal outcome non-fatal outcome
80.3°
50.0
100.02)
28.6!)
38.1
66.72>
83.33) 40.03) 27.3 28.6
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quencies of occurrence of elevated quantities in the
fatal and non-fatal groups were highly significant for
fibrin monomers (80.3% versus 28.6%) in the cerebral
haemorrhage patients, for D-dimer in the haemor-
rhage group (100% versus 66.7%) and for the ADP-
induced platelet aggregation in the cerebral infarction
groups (83.3% versus 40.0%). Neither group showed
a significant percentage difference for thrombin-an-
tithrombin III.
Discussion
The high number of patients taking acetylsalicylic acid
(26 out of 81) should be noted. Of the remaining 55
patients 21/31 = 67.1% of the infarction patients and
9/24 = 37.5% of the bleeding group showed unphy-
siologically elevated ADP-induced platelet aggrega-
tion. These results suggest a systemic increase of hy-
peraggregable platelets and are concordant with the
conclusions Of Uchiyama (2) on platelet function in
thrombotic cerebrovascular disorders. Taomoto et al.
(7) also found indications for platelet activation in
cerebrovascular disease by the measurement of the
platelet release marker ß-thromboglobulin, and this
finding has been confirmed by Fisher & Francis (8)
and Landi et al. (1).
Land! et al. (1) also reported that they could not find
significant differences for several haemostatic tests
between patients with ischaemic stroke and those with
haemorrhagic stroke. In particular, the coagulation
and fibrinolysis activation markers, fibrinopeptide A
and fibrin degradation products, were not signifi-
cantly different between the two groups. We tested
fibrin monomers (equivalent of fibrinopeptide A), D-
dimer (alternative for fibrin degradation products)
and thrombin-antithrombin III complex, and we also
found no significant differences between the two dis-
ease entities for these quantities.
Fibrin monomers, thrombin-antithrombin III com-
plexes and D-dimers all showed significantly en-
hanced values in the separate patient groups, com-
pared with the controls. These results are indicative
for coagulation activation with* reactive fibrinolysis.
In some cases, activation of the coagulation system
was expressed very strongly, Thus in 5/47 patients
with brain infarct and in 3/34 patients with cerebral
haemorrhage a fibrin monomer concentration of
> 30 nmol/1 was measured. Such a situation can be
seen as a state of low grade disseminated intravascular
coagulation and is concordant with the results on this
topic reported by Landi et al. (1).
Moreover we found that the processes of coagulation
activation and reactive fibrinolysis can be very long
lasting. The prolonged elevation of fibrin monomers,
thrombin-antithrombin III and D^dimer concentra-
tions can continue for up to four weeks in some
patients (results not shown).
In summary, the results of the present study suggest
a state of hypercoagulability after the onset of stroke.
Hypercoagulability leads to the formation of throm-
bin, which is demonstrated by the elevation of fibrin
monomer, thrombin-antithrombin III and activated
platelets. Whether the haemostatic and fibrinolytic
abnormalities preceed stroke and/or possibly contrib-
ute to its pathogenesis cannot be concluded from this
study. The extent of the necrosis of cerebral tissue
might also play a part in the processes after onset of
stroke. Nevertheless, the level of hypercoagulability
in the first phase after stroke, as shown in the present
study, can be considered to be a clinically relevant,
negative prognostic factor, as already stated by Landi
et al. (1). It therefore appears expedient to determine
the haemostatic quantities described in this study in
the acute phase of patients with stroke.
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